Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for folic acid
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on folic acid or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on folic acid and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
Effect of peri-conceptional folicacid supplementation for prevention of stillbirths due to neural tube defects in low-income countries: a meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content
Effect of high dose folicacid supplementation in pregnancy on pre-eclampsia (FACT): double blind, phase III, randomised controlled, international, multicentre trial. To determine the efficacy of high dose folicacid supplementation for prevention of pre-eclampsia in women with at least one risk factor: pre-existing hypertension, prepregnancy diabetes (type 1 or 2), twin pregnancy, pre-eclampsia in a previous pregnancy, or body mass index ≥35.Randomised, phase III, double blinded international (...) , multicentre clinical trial.70 obstetrical centres in five countries (Argentina, Australia, Canada, Jamaica, and UK).2464 pregnant women with at least one high risk factor for pre-eclampsia were randomised between 2011 and 2015 (1144 to the folicacid group and 1157 to the placebo group); 2301 were included in the intention to treat analyses.Eligible women were randomised to receive either daily high dose folicacid (four 1.0 mg oral tablets) or placebo from eight weeks of gestation to the end of week 16
Folicacid Top results for folicacid - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2 (...) ) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for folicacid The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms
Is folicacid supplementation useful for chronic kidney disease? Patients with chronic kidney disease have higher cardiovascular risk than general population, a fact that has been linked to high homocysteine levels. Folicacid supplementation can reduce homocysteine levels, which would reduce cardiovascular events. However, there is controversy about the clinical effects of this measure. Searching in Epistemonikos database, which is maintained by screening 30 databases, we identified six (...) systematic reviews comprising 13 trials addressing the question of this article. We combined the evidence using meta-analysis and generated a summary of findings following the GRADE approach. We concluded folicacid supplementation does not reduce the risk of myocardial infarction or stroke in patients with chronic kidney disease, and might have no effect on mortality.
FolicAcid Supplementation for the Prevention of Neural Tube Defects: An Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. Neural tube defects are among the most common congenital anomalies in the United States. Periconceptional folicacid supplementation is a primary care-relevant preventive intervention.To review the evidence on folicacid supplementation for preventing neural tube defects to inform the US Preventive Services Task Force for an updated (...) Recommendation Statement.MEDLINE, Cochrane Library, EMBASE, and trial registries through January 28, 2016, with ongoing surveillance through November 11, 2016; references; experts.English-language studies of folicacid supplementation in women. Excluded were poor-quality studies; studies of prepubertal girls, men, women without the potential for childbearing, and neural tube defect recurrence; and studies conducted in developing countries.Two investigators independently reviewed abstracts, full-text articles
FolicAcid Supplementation for the Prevention of Neural Tube Defects: US Preventive Services Task Force Recommendation Statement. Neural tube defects are among the most common major congenital anomalies in the United States and may lead to a range of disabilities or death. Daily folicacid supplementation in the periconceptional period can prevent neural tube defects. However, most women do not receive the recommended daily intake of folate from diet alone.To update the 2009 US Preventive (...) Services Task Force (USPSTF) recommendation on folicacid supplementation in women of childbearing age.In 2009, the USPSTF reviewed the effectiveness of folicacid supplementation in women of childbearing age for the prevention of neural tube defects in infants. The current review assessed new evidence on the benefits and harms of folicacid supplementation.The USPSTF assessed the balance of the benefits and harms of folicacid supplementation in women of childbearing age and determined that the net
FolicAcid for the Prevention of Neural Tube Defects: Preventive Medication Final Recommendation Statement: FolicAcid for the Prevention of Neural Tube Defects: Preventive Medication - US Preventive Services Task Force Search USPSTF Website Text size: Assembly version: 126.96.36.1998 Last Build: 11/16/2018 6:27:19 PM You are here: Final Recommendation Statement : Final Recommendation Statement Final Recommendation Statement FolicAcid for the Prevention of Neural Tube Defects: Preventive Medication (...) Recommendations made by the USPSTF are independent of the U.S. government. They should not be construed as an official position of the Agency for Healthcare Research and Quality or the U.S. Department of Health and Human Services. Recommendation Summary Population Recommendation Grade Women who are planning or capable of pregnancy The USPSTF recommends that all women who are planning or capable of pregnancy take a daily supplement containing 0.4 to 0.8 mg (400 to 800 µg) of folicacid. To read
Association of neural tube defects and folicacid food fortification in Canada. Many women do not receive folicacid supplements before conception. In response, most of Canada's cereal grain products were being fortified with folicacid by January, 1998, thereby providing an additional 0.1-0.2 mg per day of dietary folate to the Canadian population. We assessed the effect of supplementation on prevalence of open neural tube defects in the province of Ontario. Among 336 963 women who underwent (...) maternal serum screening over 77 months, the prevalence of open neural tube defects declined from 1.13 per 1000 pregnancies before fortification to 0.58 per 1000 pregnancies thereafter (prevalence ratio 0.52, 95% CI 0.40-0.67, p<0.0001). At a population level, folicacid food fortification is associated with a pronounced reduction in open neural tube defects.
The evaluation of serum homocysteine, folicacid, and vitamin B12 in patients complicated with preeclampsia Increased plasma homocysteine may be associated with adverse pregnancy outcomes, such as preeclampsia. The aim of this study was to determine the plasma homocysteine, serum folate, and vitamin B12 levels in preeclamptic pregnant women.This case-control study was conducted in 2016 in Ahwaz on 51 pregnant women with preeclampsia and 51 healthy pregnant women of the same gestational age, who (...) served as controls. The case group also was subdivided into severe and non-severe preeclampsia. Patients' data were collected through a questionnaire and medical records. Serum homocysteine, folicacid, and vitamin B12 were analyzed using chemiluminescent assay. The results were compared between two groups. Statistical analyses were done using IBM-SPSS 20.0. A Kolmogorov-Smirnov test, independent samples t-test, Mann-Whitney test, and Chi-square test were used for data analysis.No different
Effect of FolicAcid therapy on Homocysteine Level in patients with Atherosclerosis or Buergerâ€™s Disease and in Healthy individuals: A clinical trial Hyperhomocysteinemia is considered a risk factor for atherosclerosis and some other vascular diseases such as Buerger's disease.The aim of this study was to measure the Homocysteine levels in 3 different groups of participants (Buerger's disease, atherosclerosis patients, and healthy cases) and determine the therapeutic effect of folicacid (...) and after 12 weeks of folicacid (5mg/day) therapy. The data analysis used fo data analysis was a Chi square and t-test or their non-parametrical equivalents for data analysis by means of Statistical Package for the Social Sciences (SPSS) version 16.The homocysteine levels were found to be significantly higher in patients with Buerger's disease as compared to other groups before treatment with folicacid (Buerger = 21.8 ± 8.5 Mm/L, atherosclerosis = 17.3 ± 6.9, healthy = 13.8 ± 3.1; p < 0.001). After
Efficacy of FolicAcid Therapy on the Progression of Chronic Kidney Disease: The Renal Substudy of the China Stroke Primary Prevention Trial The efficacy of folicacid therapy on renal outcomes has not been previously investigated in populations without folicacid fortification.To test whether treatment with enalapril and folicacid is more effective in slowing renal function decline than enalapril alone across a spectrum of renal function at baseline from normal to moderate chronic kidney (...) disease (CKD) among Chinese adults with hypertension.In this substudy of eligible China Stroke Primary Prevention Trial (CSPPT), 15 104 participants with an estimated glomerular filtration rate (eGFR) 30 mL/min/1.73 m2 or greater, including 1671 patients with CKD, were recruited from 20 communities in Jiangsu province in China.Participants were randomized to receive a single tablet daily containing 10 mg enalapril and 0.8 mg folicacid (n = 7545) or 10 mg enalapril alone (n = 7559).The primary outcome
Efficacy of folicacid therapy in primary prevention of stroke among adults with hypertension in China: the CSPPT randomized clinical trial. Uncertainty remains about the efficacy of folicacid therapy for the primary prevention of stroke because of limited and inconsistent data.To test the primary hypothesis that therapy with enalapril and folicacid is more effective in reducing first stroke than enalapril alone among Chinese adults with hypertension.The China Stroke Primary Prevention Trial (...) , a randomized, double-blind clinical trial conducted from May 19, 2008, to August 24, 2013, in 32 communities in Jiangsu and Anhui provinces in China. A total of 20,702 adults with hypertension without history of stroke or myocardial infarction (MI) participated in the study.Eligible participants, stratified by MTHFR C677T genotypes (CC, CT, and TT), were randomly assigned to receive double-blind daily treatment with a single-pill combination containing enalapril, 10 mg, and folicacid, 0.8 mg (n = 10,348
Efficacy of FolicAcid Therapy in Primary Prevention of Stroke Among Adults With Hypertension in China: The CSPPT Randomized Clinical Trial. Uncertainty remains about the efficacy of folicacid therapy for the primary prevention of stroke because of limited and inconsistent data.To test the primary hypothesis that therapy with enalapril and folicacid is more effective in reducing first stroke than enalapril alone among Chinese adults with hypertension.The China Stroke Primary Prevention Trial (...) , a randomized, double-blind clinical trial conducted from May 19, 2008, to August 24, 2013, in 32 communities in Jiangsu and Anhui provinces in China. A total of 20,702 adults with hypertension without history of stroke or myocardial infarction (MI) participated in the study.Eligible participants, stratified by MTHFR C677T genotypes (CC, CT, and TT), were randomly assigned to receive double-blind daily treatment with a single-pill combination containing enalapril, 10 mg, and folicacid, 0.8 mg (n = 10,348
Pre-conception FolicAcid and Multivitamin Supplementation for the Primary and Secondary Prevention of Neural Tube Defects and Other FolicAcid-Sensitive Congenital Anomalies Pre-conception FolicAcid and Multivitamin Supplementation for the Primary and Secondary Prevention of Neural Tube Defects and Other FolicAcid-Sensitive Congenital Anomalies - Journal of Obstetrics and Gynaecology Canada Email/Username: Password: Remember me Search Terms Search within Search Volume 37, Issue 6, Pages 534 (...) –549 Pre-conception FolicAcid and Multivitamin Supplementation for the Primary and Secondary Prevention of Neural Tube Defects and Other FolicAcid-Sensitive Congenital Anomalies PRINCIPAL AUTHOR, x R. Douglas Wilson , MD Calgary AB x GENETICS COMMITTEE x R. Douglas Wilson , MD (Chair) x R. Douglas Wilson , x François Audibert , MD x François Audibert , x Jo-Ann Brock , MD x Jo-Ann Brock , x June Carroll , MD x June Carroll , x Lola Cartier , MSc x Lola Cartier , x Alain Gagnon , MD x Alain Gagnon
Effect of Maternal Multiple Micronutrient vs Iron-FolicAcid Supplementation on Infant Mortality and Adverse Birth Outcomes in Rural Bangladesh: The JiVitA-3 Randomized Trial. Maternal micronutrient deficiencies may adversely affect fetal and infant health, yet there is insufficient evidence of effects on these outcomes to guide antenatal micronutrient supplementation in South Asia.To assess effects of antenatal multiple micronutrient vs iron-folicacid supplementation on 6-month infant (...) -folicacid alone, taken daily from early pregnancy to 12 weeks postpartum.The primary outcome was all-cause infant mortality through 6 months (180 days). Prespecified secondary outcomes in this analysis included stillbirth, preterm birth (<37 weeks), and low birth weight (<2500 g). To maintain overall significance of α = .05, a Bonferroni-corrected α = .01 was calculated to evaluate statistical significance of primary and 4 secondary risk outcomes (.05/5).Among the 22,405 pregnancies in the multiple
FolicAcid USE OF FOLICACID IN PREGNANCY 0344 892 0909 USE OF FOLICACID IN PREGNANCY (Date of issue: February 2018 , Version: 2 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary Folicacid (pteroylglutamic acid/PGA) is a synthetic derivative (...) of the water-soluble form of vitamin B9 (also known as folate). It requires metabolism to dihydrofolic acid and then to its biologically active form tetrahydrofolate. Folate is necessary for the production of blood cells and DNA. Folicacid is used in the treatment of nutritional megaloblastic anaemias and prophylactically in individuals at risk of deficiency e.g. due to chronic haemolysis or renal dialysis. During pregnancy folate requirements are increased 5- to 10-fold and pregnant women are therefore
Completeness of reporting of setting and health worker cadre among trials on antenatal iron and folicacid supplementation in pregnancy: an assessment based on two Cochrane reviews. Poor reporting of medical trials has triggered the development of trial reporting standards within the scientific community. In addition to a description of the proposed intervention, adequate information about the trial setting and the group of health workers (cadre) delivering the intervention would allow a better (...) understanding of the generalizability of the trial findings, facilitate replication of trial interventions and assist with assessment of trials for inclusion in systematic reviews. This study aims to determine the completeness of reporting for trial setting and cadre among trials included in two Cochrane reviews on iron and folicacid supplementation for women during pregnancy.From the 81 trials included in the two Cochrane reviews, we extracted data on the trial setting, including the facility type
Folicacid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Methotrexate (MTX) is a disease modifying antirheumatic drug (DMARD) used as a first line agent for treating rheumatoid arthritis (RA). Pharmacologically, it is classified as an antimetabolite due to its antagonistic effect on folicacid metabolism. Many patients treated with MTX experience mucosal, gastrointestinal, hepatic or haematologic side effects. Supplementation with folic (...) or folinic acid during treatment with MTX may ameliorate these side effects.To identify trials of supplementation with folicacid or folinic acid during MTX therapy for rheumatoid arthritis and to assess the benefits and harms of folicacid and folinic acid (a) in reducing the mucosal, gastrointestinal (GI), hepatic and haematologic side effects of MTX, and (b) whether or not folic or folinic acid supplementation has any effect on MTX benefit.We originally performed MEDLINE searches, from January 1966
Effects of folicacid supplementation on overall and site-specific cancer incidence during the randomised trials: meta-analyses of data on 50 000 individuals Effects of folicacid supplementation on overall and site-specific cancer incidence during the randomised trials: meta-analyses of data on 50 000 individuals Effects of folicacid supplementation on overall and site-specific cancer incidence during the randomised trials: meta-analyses of data on 50 000 individuals Vollset SE, Clarke R (...) , Lewington S, Ebbing M, Halsey J, Lonn E, Armitage J, Manson JA, Hankey GJ, Spence JD, Galan P, Bonaa KH, Jamison R, Gaziano JM, Guarino P, Baron JA, Logan RF, Giovannucci EL, den Heijer M, Ueland PM, Bennett D, Collins R, Peto R; B-Vitamin Treatment Trialists' Collaboration CRD summary The review concluded that folicacid supplementation did not substantially increase or decrease incidence of site-specific cancer during the first five years of treatment. These conclusions represent a fair reflection
Association between maternal use of folicacid supplements and risk of autism spectrum disorders in children. Prenatal folicacid supplements reduce the risk of neural tube defects in children, but it has not been determined whether they protect against other neurodevelopmental disorders.To examine the association between maternal use of prenatal folicacid supplements and subsequent risk of autism spectrum disorders (ASDs) (autistic disorder, Asperger syndrome, pervasive developmental disorder (...) -not otherwise specified [PDD-NOS]) in children.The study sample of 85,176 children was derived from the population-based, prospective Norwegian Mother and Child Cohort Study (MoBa). The children were born in 2002-2008; by the end of follow-up on March 31, 2012, the age range was 3.3 through 10.2 years (mean, 6.4 years). The exposure of primary interest was use of folicacid from 4 weeks before to 8 weeks after the start of pregnancy, defined as the first day of the last menstrual period before conception